The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, has signed a Declaration of Collaboration with Johnson & Johnson Middle East to support the emirate’s vision of developing a regional hub for clinical research and data generation.
The new strategic collaboration seeks to bring innovative treatments and breakthrough solutions to the UAE and the Middle East and North Africa (MENA) region, as well as exchange knowledge and experiences across the healthcare sector.
Through these strategic collaborations, DoH and Johnson & Johnson Middle East will explore key potential areas of interest to develop short and long-term projects in the generation of Data and Real-World Evidence (RWE).
The Declaration of Collaboration was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, and Ms. Jamie Phares, Managing Director of Janssen GCC, one of the pharmaceutical companies of Johnson and Johnson.
Dr. Al Mannaei said that, “Our collaborations with leading healthcare companies echo Abu Dhabi’s ongoing efforts to position itself as a leading life science destination as well as an incubator for innovation. Through our collaboration with Johnson Middle East, we aim to further improve the resilience and sustainability of the healthcare sector as well as provide quality care to patients in Abu Dhabi and worldwide.”
According to the statement, “Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients.”
Recently, Abu Dhabi DoH signed a Declaration of Collaboration (DoC) with Sanofi, a French multinational healthcare company.
